ASCO 2019 Conference Review - focus on lung cancer, reviewed by A/Prof Nick Pavlakis

In this review:

RELAY shows efficacy of RAM + ERL in EGFR-mutant mNSCLC
The addition of platinum-doublet chemotherapy to gefitinib improves survival in mNSCLC
Adjuvant chemotherapy provides a benefit for patients with a high-risk of recurrence in NSCLC
Lurbinectedin in second-line SCLC patients
BLU-667 in RET-fusion positive NSCLC
TAK-788 in NSCLC with EGFR exon 20 insertions
Capmatinib shows deep and durable responses in METΔex14- mutated NSCLC
VISION: MET-inhibitor tepotinib in NSCLC
Neoadjuvant atezolizumab in resectable NSCLC
NEOSTAR shows benefit for combination anti–PD-1/anti–CTLA-4 immune checkpoint blockade pre-resection

Please login below to download this issue (PDF)